Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190495118 | Prostate | Tumor | positive regulation of establishment of protein localization | 106/3246 | 319/18723 | 3.13e-12 | 2.70e-10 | 106 |
GO:007138317 | Prostate | Tumor | cellular response to steroid hormone stimulus | 76/3246 | 204/18723 | 7.73e-12 | 6.16e-10 | 76 |
GO:003315717 | Prostate | Tumor | regulation of intracellular protein transport | 81/3246 | 229/18723 | 3.47e-11 | 2.37e-09 | 81 |
GO:003139619 | Prostate | Tumor | regulation of protein ubiquitination | 76/3246 | 210/18723 | 3.96e-11 | 2.68e-09 | 76 |
GO:001605514 | Prostate | Tumor | Wnt signaling pathway | 131/3246 | 444/18723 | 1.16e-10 | 7.11e-09 | 131 |
GO:019873814 | Prostate | Tumor | cell-cell signaling by wnt | 131/3246 | 446/18723 | 1.61e-10 | 9.69e-09 | 131 |
GO:000691316 | Prostate | Tumor | nucleocytoplasmic transport | 97/3246 | 301/18723 | 1.78e-10 | 1.05e-08 | 97 |
GO:005116916 | Prostate | Tumor | nuclear transport | 97/3246 | 301/18723 | 1.78e-10 | 1.05e-08 | 97 |
GO:005122218 | Prostate | Tumor | positive regulation of protein transport | 97/3246 | 303/18723 | 2.67e-10 | 1.48e-08 | 97 |
GO:190018014 | Prostate | Tumor | regulation of protein localization to nucleus | 53/3246 | 136/18723 | 1.72e-09 | 7.91e-08 | 53 |
GO:003238817 | Prostate | Tumor | positive regulation of intracellular transport | 70/3246 | 202/18723 | 2.01e-09 | 8.86e-08 | 70 |
GO:190018214 | Prostate | Tumor | positive regulation of protein localization to nucleus | 39/3246 | 87/18723 | 2.24e-09 | 9.59e-08 | 39 |
GO:003011114 | Prostate | Tumor | regulation of Wnt signaling pathway | 99/3246 | 328/18723 | 5.92e-09 | 2.34e-07 | 99 |
GO:009031614 | Prostate | Tumor | positive regulation of intracellular protein transport | 57/3246 | 160/18723 | 2.01e-08 | 7.03e-07 | 57 |
GO:006082814 | Prostate | Tumor | regulation of canonical Wnt signaling pathway | 79/3246 | 253/18723 | 4.01e-08 | 1.25e-06 | 79 |
GO:004682216 | Prostate | Tumor | regulation of nucleocytoplasmic transport | 42/3246 | 106/18723 | 4.65e-08 | 1.43e-06 | 42 |
GO:001657013 | Prostate | Tumor | histone modification | 126/3246 | 463/18723 | 5.51e-08 | 1.65e-06 | 126 |
GO:003052217 | Prostate | Tumor | intracellular receptor signaling pathway | 81/3246 | 265/18723 | 7.65e-08 | 2.14e-06 | 81 |
GO:003051815 | Prostate | Tumor | intracellular steroid hormone receptor signaling pathway | 44/3246 | 116/18723 | 1.02e-07 | 2.72e-06 | 44 |
GO:190332119 | Prostate | Tumor | negative regulation of protein modification by small protein conjugation or removal | 38/3246 | 95/18723 | 1.49e-07 | 3.76e-06 | 38 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa04120 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041201 | Colorectum | AD | Ubiquitin mediated proteolysis | 58/2092 | 142/8465 | 1.46e-05 | 1.53e-04 | 9.76e-05 | 58 |
hsa041202 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041203 | Colorectum | SER | Ubiquitin mediated proteolysis | 39/1580 | 142/8465 | 6.18e-03 | 3.66e-02 | 2.66e-02 | 39 |
hsa041204 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041205 | Colorectum | MSS | Ubiquitin mediated proteolysis | 55/1875 | 142/8465 | 5.02e-06 | 6.00e-05 | 3.68e-05 | 55 |
hsa041206 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041207 | Colorectum | FAP | Ubiquitin mediated proteolysis | 51/1404 | 142/8465 | 1.55e-08 | 5.84e-07 | 3.55e-07 | 51 |
hsa041208 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa041209 | Colorectum | CRC | Ubiquitin mediated proteolysis | 42/1091 | 142/8465 | 9.98e-08 | 6.67e-06 | 4.52e-06 | 42 |
hsa0412016 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412017 | Endometrium | AEH | Ubiquitin mediated proteolysis | 41/1197 | 142/8465 | 3.42e-06 | 4.27e-05 | 3.13e-05 | 41 |
hsa0412023 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412033 | Endometrium | EEC | Ubiquitin mediated proteolysis | 41/1237 | 142/8465 | 7.86e-06 | 9.58e-05 | 7.14e-05 | 41 |
hsa0412026 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa04120111 | Esophagus | HGIN | Ubiquitin mediated proteolysis | 49/1383 | 142/8465 | 7.78e-08 | 1.33e-06 | 1.06e-06 | 49 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UBR5 | SNV | Missense_Mutation | novel | c.5624N>T | p.Ser1875Phe | p.S1875F | O95071 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
UBR5 | SNV | Missense_Mutation | novel | c.5161A>C | p.Thr1721Pro | p.T1721P | O95071 | protein_coding | tolerated(0.08) | benign(0) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
UBR5 | SNV | Missense_Mutation | | c.1608N>T | p.Leu536Phe | p.L536F | O95071 | protein_coding | deleterious(0.01) | possibly_damaging(0.656) | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
UBR5 | SNV | Missense_Mutation | novel | c.1367C>T | p.Ser456Phe | p.S456F | O95071 | protein_coding | tolerated(0.12) | benign(0.094) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UBR5 | SNV | Missense_Mutation | | c.7679N>T | p.Gly2560Val | p.G2560V | O95071 | protein_coding | deleterious(0) | possibly_damaging(0.908) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
UBR5 | SNV | Missense_Mutation | novel | c.5161N>C | p.Thr1721Pro | p.T1721P | O95071 | protein_coding | tolerated(0.08) | benign(0) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
UBR5 | SNV | Missense_Mutation | | c.1795N>C | p.Lys599Gln | p.K599Q | O95071 | protein_coding | tolerated(0.07) | probably_damaging(0.95) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
UBR5 | SNV | Missense_Mutation | novel | c.2473N>T | p.Asp825Tyr | p.D825Y | O95071 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UBR5 | SNV | Missense_Mutation | | c.6185N>A | p.Arg2062Lys | p.R2062K | O95071 | protein_coding | tolerated(0.19) | possibly_damaging(0.815) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
UBR5 | SNV | Missense_Mutation | novel | c.5161N>C | p.Thr1721Pro | p.T1721P | O95071 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AO-A12H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |